Prospective Comparative Study to Compare the Efficacy And Safety of Oral Itraconazole and Oral Terbinafine in Relation With Clinical and Mycological Clearance.

Background: There has been an alarming increase in recalcitrant dermatophytosis in recent years. The standard treatment guidelines no longer seem effective in achieving clearance and results in high failure rates. Methods: The present study was Prospective comparative study conducted in department of dermatology and venereology and leprology, Patna Medical College and Hospital, Patna, among patients attending in outpatients department. The study was conducted from august 2020 to august 2021. After getting institutional ethical committees’ approval for the use of oral itraconazole and oral terbinafine in patients of dermatophytosis. The patients were allocated into two groups: GROUP I: Daily dose of terbinafine 250mg BD daily for 4 weeks and continue with treatment during follow for 8wk if not cured. GROUP II: Daily dose of itraconazole 100mg BDdaily for 4 weeks and continue with treatment during follow up for 8wk if not cured. Results: This was prospective comparative study of oral Itraconazole and oral terbinafine in patients of Dermatophytosis. The most commonly affected age group was highly productive and working population that was 21-30yrs. By taking 9 point assessment score the severity of lesions were assessed and graded accordingly. On 4 wks of follow up there was reduction of dermoscopic evidence, 34 % and 42% in Group I and group II respectively. At the end of study(8weeks) dermoscopic features of dermatophytosis reduced by 87 % and 91% n group I and group II respectively. Conclusions: It was found that Itraconazole was more efficacious than Terbinafine Although Terbinafine is fungicidal drug with more chances of drug resistance and Itraconazoleis fungistatic with less chances of drug resistance. However, with both drugs the clinical, mycological and dermoscopic cure took more time from the conventional dosage and treatment duration because the patient was treated with only oral therapy without any topical antifungal drugs. [ABSTRACT FROM AUTHOR]

Copyright of European Journal of Cardiovascular Medicine is the property of Healthcare Bulletin and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)